Nicole Pribut

Nicole Pribut

Auto-generated profile, based on publicly available information

Nicole Pribut

Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NPNicole Pribut
Nicole Pribut
CVClinton Veale
Clinton Veale
ABAdriaan Erasmus Basson
Adriaan Erasmus Basson
WOWillem A.L. van Otterlo
Willem A.L. van Otterlo
SPStephen C. Pelly
Stephen C. Pelly

17 January 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NPNicole Pribut
Nicole Pribut
ABAdriaan E. Basson
Adriaan E. Basson
WOWillem A. L. van Otterlo
Willem A. L. van Otterlo
Dennis LiottaDennis Liotta
Dennis Liotta
SPStephen C. Pelly
Stephen C. Pelly

1 March 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SBSiobhan Brigg
Siobhan Brigg
NPNicole Pribut
Nicole Pribut
ABAdriaan Erasmus Basson
Adriaan Erasmus Basson
MAMoscos Avgenikos
Moscos Avgenikos
RVReinhardt Venter
Reinhardt Venter
SPStephen C. Pelly
Stephen C. Pelly

30 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NPNicole Pribut
Nicole Pribut
MDMichael D’eRasmo
Michael D’eRasmo
MDMadhuri Dasari
Madhuri Dasari
KGKyle E. Giesler
Kyle E. Giesler
SISabrina Iskandar
Sabrina Iskandar
EMEric J. Miller
Eric J. Miller

1 September 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RMRonel Müller
Ronel Müller
IMIqbal Mulani
Iqbal Mulani
ABAdriaan Erasmus Basson
Adriaan Erasmus Basson
NPNicole Pribut
Nicole Pribut
MHMohammad Hassam
Mohammad Hassam
SPStephen C. Pelly
Stephen C. Pelly

28 September 2023 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
LJLeon Jacobs
Leon Jacobs
AWAletta van der Westhuyzen
Aletta van der Westhuyzen
NPNicole Pribut
Nicole Pribut
ZDZackery W. Dentmon
Zackery W. Dentmon
DCDan Cui
Dan Cui
Dennis LiottaDennis Liotta
Dennis Liotta
The SARS-CoV-2 main protease (Mpro) has been proven to be a highly effective target for therapeutic intervention, yet only one drug currently holds FDA approval status for this target. We were inspired by a series of publications emanating from the Jorgensen and Anderson groups describing the design of potent, non-peptidic, competitive SARS-CoV-2 Mpro inhibitors, and we saw an opportunity to make several design modifications to improve the overall pharmacokinetic profile of these compounds without losing potency. To this end, we created a focused virtual library using reaction-based enumeration tools in the Schrödinger suite. These compounds were docked into the Mpro active site and subsequently prioritized for synthesis based upon relative binding affinity values calculated by FEP+. Fourteen compounds were selected, synthesized, and evaluated both biochemically and in cell culture. Several of the synthesized compounds proved to be potent, competitive Mpro inhibitors with improved metabolic stability profiles.